Isotonitazene

asthma, COPD, sleep apnea, obesity hypoventilation syndrome

Any condition reducing baseline respiratory function — including asthma, COPD, sleep apnea, or obesity hypoventilation syndrome — increases the risk of fatal respiratory depression from MOR agonism. Respiratory depression is the primary documented cause of death in all isotonitazene fatalities.

cirrhosis, hepatitis, severe hepatic insufficiency

The primary metabolic pathways (N-deethylation, O-dealkylation) are consistent with CYP3A4 and CYP2D6 involvement. Hepatic impairment could reduce clearance, increasing exposure to both parent compound and the active metabolite N-desethyl isotonitazene, which is more potent at MOR than the parent. No direct CYP phenotyping studies have been published for isotonitazene.

chronic kidney disease, acute renal failure, dialysis patients

Renal impairment may reduce excretion of isotonitazene metabolites, potentially prolonging pharmacological activity. The active metabolite N-desethyl isotonitazene is more potent than the parent compound, so impaired renal clearance could extend the duration and severity of effects. No isotonitazene-specific renal data exist.

flualprazolam, diazepam, alprazolam, clonazepam, all benzodiazepines and designer benzodiazepines

Benzodiazepine co-use is the single most dangerous pharmacodynamic interaction documented for isotonitazene. Norwegian forensic data show >90% of nitazene fatalities involved polydrug combinations, with designer benzodiazepines (especially flualprazolam) detected in 50% of cases. The mechanism is synergistic respiratory depression: GABA-A receptor potentiation combined with MOR-mediated brainstem depression.

fentanyl, morphine, heroin, oxycodone, methadone, all MOR agonists

Co-administration with any other opioid agonist produces additive or synergistic respiratory depression through the same MOR-dependent pathway. Polydrug opioid detection is documented in postmortem forensic case series. Given isotonitazene's extreme potency (~3.7× fentanyl, ~1,500× morphine), even trace additional opioid exposure may be fatal.

ethanol

Alcohol co-ingestion produces synergistic CNS and respiratory depression. Ethanol is documented in polydrug nitazene fatality patterns in Norwegian and broader European forensic casework.

phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide, all MAO inhibitors

Co-administration of opioids with monoamine oxidase inhibitors carries risk of serotonin syndrome-like reactions and potentiated CNS depression across the opioid class. No isotonitazene-specific data exist; this contraindication is class-inferred from MOR full agonist pharmacology.